Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRd induction followed by ixazomib-lenalidomide-based continuous therapy in young newly diagnosed multiple myeloma
ChiCTR2000038075Phase 4Recruiting
- Sponsor
- The First Hospital of Fujian Medical University
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, lenalidomide, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by The First Hospital of Fujian Medical University. Primary endpoint: Progression-free survival. Started Sep 2020; status: recruiting.
02
Drugs
ixazomiblenalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2000038075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038075.